We would like to thank Dr. Zanetto and colleagues for their interest in our work and
for sharing their valuable findings in regard to plasma von Willebrand factor antigen
(VWF:Ag) levels in patients with acute decompensation (AD) and their lack of association
with acute-on-chronic liver failure (ACLF) development and death [
[1]
].- Zanetto A.C.E
- Bulato C.
- Burra P.
- Senzolo M.
- Simioni P
Von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis
is increased but not associated with development of ACLF.
Dig Liver Dis. 2022; (in print)https://doi.org/10.1016/j.dld.2022.10.001
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLF.Dig Liver Dis. 2022; (in print)https://doi.org/10.1016/j.dld.2022.10.001
- Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.Aliment Pharmacol Ther. 2018; 47: 980-988
- Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.Dig Liver Dis. 2022; 54: 1376-1384
- Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.Liver Int. 2015; 35 (official journal of the International Association for the Study of the Liver): 37-45
- Decreasing von Willebrand factor levels upon nonselective beta blocker therapy indicate a decreased risk of further decompensation, acute-on-chronic liver failure, and death.Clin Gastroenterol Hepatol. 2022; 20 (the official clinical practice journal of the American Gastroenterological Association): 1362-1373
- The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.J Hepatol. 2020; 73: 842-854
- Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.United Eur Gastroenterol J. 2021; 9: 427-437
- Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease.J Thromb Haemost JTH. 2021; 19: 85-95
- Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.J Hepatol. 2022; (In press)
- Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.J Hepatol. 2022; 76: 1090-1099
- Noninvasive diagnostics for portal hypertension: a comprehensive review.Semin Liver Dis. 2020; 40: 240-255
- The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension.Clin Gastroenterol Hepatol. 2022; (the official clinical practice journal of the American Gastroenterological Association In press)
- The addition of C-reactive protein and von willebrand factor to MELD-Na improves prediction of waitlist mortality.Hepatology. 2021; 74 (Baltimore, Md): 1533-1545
Article Info
Publication History
Published online: November 12, 2022
Accepted:
October 24,
2022
Received:
October 18,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLFDigestive and Liver Disease
- PreviewWe read with interest the original article by Pomej et al, which was recently published in Digestive and Liver Disease [1]. In a large, retrospective cohort of clinically stable patients with cirrhosis, these Authors demonstrated that a “substantially elevated” level of von Willebrand factor antigen (i.e.: >420%) was predictive of hepatic decompensation and liver-related mortality independently of age, etiology of liver disease, Child-Pugh stage, severity of portal hypertension, serum creatine, and C-reactive protein [1].
- Full-Text
- Preview
- Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver diseaseDigestive and Liver DiseaseVol. 54Issue 10
- PreviewVon Willebrand factor antigen (VWF) is a non-invasive marker for clinically significant portal hypertension (HVPG≥10 mmHg) and confers HVPG-independent prognostic information. While quantification of increased VWF-levels is not relevant in the context of von Willebrand disease, highly elevated VWF may be of clinical significance in ACLD. Thus, we have modified our analytical approach to quantify very high VWF-levels (i.e.,>420%) and investigated their prognostic value.
- Full-Text
- Preview
